A Phase 2, Single-arm, Open-label, Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients with Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell (HSC) Transplantation (HSCT)

Administered By

Awarded By

Contributors

Start/End

  • October 30, 2018 - September 30, 2020